| Bioactivity | Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma[1][2]. |
| Name | Enfortumab vedotin-ejfv (solution) |
| CAS | 1346452-25-2 |
| Appearance | 液体 |
| Transport | Shipping with dry ice. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Halford Z, et al. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother. 2021 Jun;55(6):772-782. [2]. Chang E, et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Feb 15;27(4):922-927. |
Enfortumab vedotin-ejfv (solution)
CAS: 1346452-25-2 F: W:
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinom
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.